Overview

A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children

Status:
Terminated
Trial end date:
2016-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to support selection of an appropriate safe and efficacious dose for study in further development.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Pharmaceutical Industries
Teva Pharmaceutical Industries, Ltd.
Treatments:
Hormones